Research programme: obesity therapy - ConjuChemAlternative Names: CJC 1643; CJC 1682; DAC PYY3-36; Obesity therapy research programme - ConjuChem
Latest Information Update: 30 Jun 2006
At a glance
- Originator ConjuChem Biotechnologies
- Mechanism of Action Neuropeptide Y2 receptor agonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Obesity
Most Recent Events
- 30 Jun 2006 Discontinued - Preclinical for Obesity in Canada (unspecified route)
- 04 Jul 2005 Preclinical trials in Obesity in Canada (unspecified route)